AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TLRY · NASDAQ · Drug Manufacturers - Specialty & Generic

Tilray Brands (TLRY)

Sells cannabis, beverages, distribution and wellness products across regulated consumer markets.

$4.21

vs last close+0.13 (+3.06%)

In millions of USD, except per-share figures

In millions	Q1 FY24Aug 2023	Q2 FY24Nov 2023	Q3 FY24Feb 2024	Q4 FY24May 2024	Q1 FY25Aug 2024	Q2 FY25Nov 2024	Q3 FY25Feb 2025	Q4 FY25May 2025	Q1 FY26Aug 2025	Q2 FY26Nov 2025	Q3 FY26Feb 2026	Q4 FY26May 2026
Revenue	240	262	256	313	270	295	268	308	288	304	282	282
Cost of revenue	180	198	189	201	189	209	193	215	209	224	207	197
Gross profit	60	64	67	112	81	86	75	93	79	80	75	84
	106	121	178	135	130	145	1,173	2,074	76	111	102	89
Research & development	0	0	0	1	0	0	0	0	0	0	0	0
	76	81	83	100	91	101	87	82	88	102	95	89
Selling & marketing	21	23	29	35	31	36	30	32	32	30	26	27
General & administrative	55	59	54	65	60	65	57	50	57	72	69	61
Other expenses	31	39	95	34	39	43	1,086	1,992	−12	9	7	0
Operating income	−47	−57	−111	−23	−49	−59	−1,098	−1,981	3	−31	−27	−4
	−19	−11	−35	−36	4	−57	−47	70	−4	−25	—	−20
Interest expense	13	12	12	13	13	11	12	5	9	8	7	7
Other non-operating income	6	−1	23	6	−17	47	35	−91	−5	17	—	0
Income before tax	−66	−67	−146	−59	−46	−116	−1,144	−1,912	−1	−56	−32	−24
Income tax expense	10	−5	−4	−38	1	3	2	−172	—	5	3	14
Net income from continuing operations	−76	−63	−142	−21	−47	−119	−1,146	−1,740	2	−61	−34	−38
Net income	−97	−66	−126	−43	−53	−119	−1,140	−1,747	0	−63	−36	−50
EPS, basic	−$1.35	−$0.95	−$1.63	−$0.55	−$0.54	−$1.40	−$12.60	−$17.80	−$0.00	−$0.57	−$0.33	−$0.43
EPS, diluted	−$1.35	−$0.95	−$1.63	−$0.55	−$0.54	−$1.40	−$12.60	−$17.80	−$0.00	−$0.57	−$0.33	−$0.43
Weighted average shares, basic	69	73	75	79	88	86	91	98	106	110	113	112
Weighted average shares, diluted	69	73	75	79	88	86	91	98	106	110	113	112
EBITDA	−11	−13	−90	15	11	−58	−1,084	−1,844	30	−26	−2	15
Depreciation & amortization	42	43	45	43	43	48	48	47	21	22	23	19
EBIT	−53	−55	−135	−28	−32	−106	−1,132	−1,890	8	−48	−25	−4